Study identifier:BY217/M2-013
ClinicalTrials.gov identifier:NCT00163527
EudraCT identifier:N/A
CTIS identifier:N/A
A 24-Week, Double-Blind, Parallel Group, Placebo and Active Controlled Study to Investigate the Efficacy and Safety of Daily Oral Roflumilast Taken with Low Dose Inhaled Corticosteroids in Patients with Chronic Asthma
asthma
Phase 3
No
Roflumilast
All
2054
Interventional
12 Years - 70 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verified 01 Sept 2016 by AstraZeneca
AstraZeneca
Pfizer
No locations available
Arms | Assigned Interventions |
---|